Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas. Efficacy of DTIC in cases which fail to respond to conventional chemotherupetic combinations.
15 patients with malignant lymphomas (stage III B or IV) who had become resistant to previous combination chemotherapy were treated with DTIC. The drug was administered intravenously as a single agent in doses of 300 mg/m2 on 5 consecutive days, once a month. The results demonstrate good responses in Hodgkin's disease, while in non-Hodgkin's lymphomas only incomplete and short remissions or failures were recorded. The only untoward side effects were nausea, vomiting and pain in the vein during the injection.